Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 19883882)

1.

Erythropoiesis-stimulating agents in anemia: use and misuse.

Dharmarajan TS, Widjaja D.

J Am Med Dir Assoc. 2009 Nov;10(9):607-16. doi: 10.1016/j.jamda.2009.05.003. Review.

PMID:
19883882
3.

Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.

Kapoian T.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S21-8. doi: 10.1053/j.ajkd.2008.09.004.

PMID:
19010258
4.

The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?

Singh AK.

Am J Kidney Dis. 2008 Dec;52(6 Suppl):S5-13. doi: 10.1053/j.ajkd.2008.09.010.

PMID:
19010260
5.

The new label for erythropoiesis stimulating agents: the FDA'S sentence.

Fishbane S, Jhaveri KD.

Semin Dial. 2012 May;25(3):263-6. doi: 10.1111/j.1525-139X.2012.01065.x. Epub 2012 Apr 20.

PMID:
22515844
6.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

8.

Anemia and the potential role of erythropoiesis-stimulating agents in heart failure.

Faraz HA, Zafar SF, Ghali JK.

Curr Heart Fail Rep. 2008 Jun;5(2):83-90. Review.

PMID:
18765078
9.
10.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
11.

Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.

Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP.

Am J Kidney Dis. 2009 May;53(5):823-34. doi: 10.1053/j.ajkd.2008.12.040. Epub 2009 Apr 1.

12.

An economic evaluation of erythropoiesis-stimulating agents in CKD.

Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ.

Am J Kidney Dis. 2010 Dec;56(6):1050-61. doi: 10.1053/j.ajkd.2010.07.015. Epub 2010 Oct 8.

PMID:
20932621
13.
14.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014. Epub 2012 Aug 22.

15.

Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.

Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P.

Nephrol Dial Transplant. 2012 Feb;27(2):709-15. doi: 10.1093/ndt/gfr288. Epub 2011 May 26.

16.

Changing patterns of anemia management in US hemodialysis patients.

Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA.

Am J Med. 2012 Sep;125(9):906-14.e9. doi: 10.1016/j.amjmed.2012.03.011.

PMID:
22938926
17.

Erythropoietic stimulating agents.

Testa U.

Expert Opin Emerg Drugs. 2010 Mar;15(1):119-38. doi: 10.1517/14728210903499273. Review.

PMID:
20158404
18.

The new FDA labeling for ESA--implications for patients and providers.

Manns BJ, Tonelli M.

Clin J Am Soc Nephrol. 2012 Feb;7(2):348-53. doi: 10.2215/CJN.09960911. Epub 2012 Jan 19.

19.

Anemia of chronic kidney disease: when normalcy becomes undesirable.

Demirjian SG, Nurko S.

Cleve Clin J Med. 2008 May;75(5):353-6.

PMID:
18556877
20.

Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.

Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB; ESA Clinic Study Group.

Am J Kidney Dis. 2012 Sep;60(3):371-9. doi: 10.1053/j.ajkd.2012.04.013. Epub 2012 May 26.

PMID:
22633556
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk